These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis. Joshita S; Umemura T; Ota M; Tanaka E J Hepatol; 2014 Dec; 61(6):1443-5. PubMed ID: 25152209 [No Abstract] [Full Text] [Related]
4. Reply to: "AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis". Trivedi PJ; Bruns T; Li KK; Hirschfield GM J Hepatol; 2014 Dec; 61(6):1445-6. PubMed ID: 25152206 [No Abstract] [Full Text] [Related]
5. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Lindor K N Engl J Med; 2007 Oct; 357(15):1524-9. PubMed ID: 17928600 [No Abstract] [Full Text] [Related]
9. Clinical studies with silymarin: fibrosis progression is the end point. Schuppan D; Hahn EG Hepatology; 2001 Feb; 33(2):483-4. PubMed ID: 11172360 [No Abstract] [Full Text] [Related]
10. Triple therapy for patients with primary biliary cirrhosis with progressive disease despite ursodeoxycholic acid: another step forward. Kaplan MM; Bonis PA Gastroenterol Clin Biol; 2010; 34(4-5):239-41. PubMed ID: 20462715 [No Abstract] [Full Text] [Related]
11. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. Poupon R; Chrétien Y; Chazouillères O; Poupon RE J Hepatol; 2005 Mar; 42(3):418-9. PubMed ID: 15710226 [No Abstract] [Full Text] [Related]
12. The ursodeoxycholic acid story in primary biliary cirrhosis. Lim AG; Jazrawi RP; Northfield TC Gut; 1995 Sep; 37(3):301-4. PubMed ID: 7590420 [No Abstract] [Full Text] [Related]
13. Ursodeoxycholic acid and long-term survival in primary biliary cirrhosis. Levy C; Angulo P Am J Gastroenterol; 2004 Feb; 99(2):269-70. PubMed ID: 15046216 [No Abstract] [Full Text] [Related]
14. The long-term beneficial effects of ursodeoxycholic acid in primary biliary cirrhosis are highly questionable. Yan G; Erik C; Gluud C Am J Gastroenterol; 2007 Feb; 102(2):464-5. PubMed ID: 17311669 [No Abstract] [Full Text] [Related]
15. Examining the increased IgM production and ursodeoxycholic acid treatment in PBC. Lazaridis KN; Larusso NF Gastroenterology; 2005 Feb; 128(2):498-500. PubMed ID: 15685560 [No Abstract] [Full Text] [Related]
16. A major step towards effective treatment evaluation in primary biliary cirrhosis. Beuers U; Lindor KD J Hepatol; 2011 Dec; 55(6):1178-80. PubMed ID: 21703168 [No Abstract] [Full Text] [Related]
18. Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis. Vítek L; Zelenková M; Brůha R Dig Liver Dis; 2010 Dec; 42(12):911-2. PubMed ID: 20619755 [No Abstract] [Full Text] [Related]
19. Primary biliary cirrhosis. Gong Y; Christensen E; Gluud C N Engl J Med; 2005 Dec; 353(25):2719-20; author reply 2719-20. PubMed ID: 16379089 [No Abstract] [Full Text] [Related]
20. Letter: biochemical response to combination anti-retroviral therapy in patients with primary biliary cirrhosis. Mason AL; Montano-Loza AJ; Saxinger L Aliment Pharmacol Ther; 2014 Jan; 39(2):236-7. PubMed ID: 24330248 [No Abstract] [Full Text] [Related] [Next] [New Search]